Pro-inflammatory Cytokine Inhibitors, such as Tocilizumab (anti-IL-6R) [28], which targets IL-6, have shown favorable outcomes in autoimmune encephalitis and neuropathies associated with PNSs, particularly in corticosteroid-resistant cases, suggesting potential for reducing chronic neuroinflammation in anti-Ri PNSs. This evidence concerns the gene IL6 and autoimmune encephalitis.